GABARAPL1 acts as a potential marker and promotes tumor proliferation and metastasis in triple negative breast cancer

Li Ran; Tao Hong; Xinhua Xiao; Liming Xie; Junlin Zhou; Gebo Wen

doi:10.18632/oncotarget.20159

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

GABARAPL1 acts as a potential marker and promotes tumor proliferation and metastasis in triple negative breast cancer

Li Ran, Tao Hong, Xinhua Xiao, Liming Xie, Junlin Zhou and Gebo Wen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:74519-74526. https://doi.org/10.18632/oncotarget.20159

Metrics: PDF 1494 views | HTML 2028 views | ?

Abstract

Li Ran1, Tao Hong1, Xinhua Xiao1, Liming Xie2, Junlin Zhou1 and Gebo Wen1

1Department of Endocrine, The First Affiliated Hospital, University of South China, Hengyang, China

2Center for Gastric Cancer Research of Human Province, The First Affiliated Hospital, University of South China, Hengyang, China

Correspondence to:

Gebo Wen, email: [email protected]

Keywords: GABARAPL1, tumor marker, triple negative breast cancer, proliferation, invasion

Received: October 31, 2016 Accepted: June 04, 2017 Published: August 10, 2017

ABSTRACT

GABA_A-receptor-associated protein like-1 (GABARAPL1) is involved in a variety of cancers. The purpose of this study was to investigate the expression, prognostic roles and functions of GABARAPL1 in triple negative breast cancer (TNBC). Quantitative real-time PCR (qRT-PCR) showed that GABARAPL1 was up regulated in both TNBC cell lines and clinical TNBC tissues. High GABARAPL1 expression level was associated with shorter overall survival (OS) and disease free survival (DFS). Furthermore, inhibition of GABARAPL1 suppressed cell proliferation, tumorigenesis, invasion and metastasis, and induced cell apoptosis. We found that metadherin (MTDH) was a downstream target of GABARAPL1. Inhibition of GABARAPL1 suppressed the mRNA and protein expression of MTDH, and overexpression of MTDH could reverse the effects of GABARAPL1 inhibition, which meant GABARAPL1 performed its function partly through MTDH. Our findings demonstrate that GABARAPL1 acts as a tumor promoter in TNBC partly through MTDH. Targeting at GABARAPL1 could be a potential therapeutic strategy for TNBC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20159

Publication Alerts

Research Papers:

GABARAPL1 acts as a potential marker and promotes tumor proliferation and metastasis in triple negative breast cancer

Abstract